Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study.
Cursiefen C, Viaud E, Bock F, Geudelin B, Ferry A, Kadlecová P, Lévy M, Al Mahmood S, Colin S, Thorin E, Majo F, Frueh B, Wilhelm F, Meyer-Ter-Vehn T, Geerling G, Böhringer D, Reinhard T, Meller D, Pleyer U, Bachmann B, Seitz B. Cursiefen C, et al. Among authors: al mahmood s. Ophthalmology. 2014 Sep;121(9):1683-92. doi: 10.1016/j.ophtha.2014.03.038. Epub 2014 May 6. Ophthalmology. 2014. PMID: 24811963 Free article. Clinical Trial.
Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration.
Cloutier F, Lawrence M, Goody R, Lamoureux S, Al-Mahmood S, Colin S, Ferry A, Conduzorgues JP, Hadri A, Cursiefen C, Udaondo P, Viaud E, Thorin E, Chemtob S. Cloutier F, et al. Among authors: al mahmood s. Invest Ophthalmol Vis Sci. 2012 Mar 9;53(3):1195-203. doi: 10.1167/iovs.11-9064. Invest Ophthalmol Vis Sci. 2012. PMID: 22323484
The antiangiogenic insulin receptor substrate-1 antisense oligonucleotide aganirsen impairs AU-rich mRNA stability by reducing 14-3-3β-tristetraprolin protein complex, reducing inflammation and psoriatic lesion size in patients.
Colin S, Darné B, Kadi A, Ferry A, Favier M, Lesaffre C, Conduzorgues JP, Al-Mahmood S, Doss N. Colin S, et al. Among authors: al mahmood s. J Pharmacol Exp Ther. 2014 Apr;349(1):107-17. doi: 10.1124/jpet.113.209346. Epub 2014 Feb 6. J Pharmacol Exp Ther. 2014. PMID: 24504098 Clinical Trial.
[Tetraspanins: a new target for antiangiogenic therapy?].
Vasse M, Colin S, Guilmain W, Creoff E, Muraine M, Vannier JP, Al-Mahmood S. Vasse M, et al. Among authors: al mahmood s. Ann Pharm Fr. 2015 Mar;73(2):100-7. doi: 10.1016/j.pharma.2014.07.002. Epub 2014 Sep 4. Ann Pharm Fr. 2015. PMID: 25745942 Review. French.
23 results